Improvement of tissue-specific distribution and biotransformation potential of nicotinamide mononucleotide in combination with ginsenosides or resveratrol.

Editorial study summary

Study type

Animal combination study

Product relevance

Direct combination research background; not evidence of clinical synergy for this finished product.

Sample or population

Male C57/BL6 mice aged 6–8 weeks; 3 animals per group per sampling time

Studied dose

NMN 500 mg/kg plus resveratrol 50 mg/kg, administered sequentially by mouth

Duration

Acute sampling at 1, 2, 4 and 6 hours

Finding

Co-administration changed tissue NAD+ responses compared with NMN alone, including higher measured levels in heart and skeletal muscle.

Limitations

Small animal experiment, not a human trial or longevity study. No resveratrol-only arm or formal interaction analysis establishing synergy. The study used a 10:1 mass ratio; this product supplies 2:1. These measurements cannot predict tissue changes at this product’s dose.

Study quality

Full text and PubMed

Funding and disclosures

Authors declared no conflicts; funding not fully assessed.

This research does not establish results for a DR.MORGAN finished product.

Reference

1. Bai LB et al. · 2022 · PMID 35844164